|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Clonidine#Contraindications]] |
| | |
| | |
| | |
| ===Contraindications===
| |
| | |
| Clonidine hydrochloride tablets should not be used in patients with known [[hypersensitivity]] to Clonidine.
| |
| | |
| ===Warnings for Withdrawal===
| |
| | |
| Patients should be instructed not to discontinue therapy without consulting their physician. Sudden cessation of Clonidine treatment has, in some cases, resulted in symptoms such as [[nervousness]], [[agitation]], [[headache]], and [[tremor]] accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma.
| |
| | |
| The likelihood of such reactions to discontinuation of Clonidine therapy appears to be greater after administration of higher doses or continuation of concomitant [[beta-blocker]] treatment and special caution is therefore advised in these situations. Rare instances of [[hypertensive encephalopathy]], [[cerebrovascular accident]]s and death have been reported after Clonidine withdrawal.
| |
| | |
| When discontinuing therapy with Clonidine hydrochloride, the physician should reduce the dose gradually over 2 to 4 days to avoid withdrawal symptomatology.
| |
| | |
| An excessive rise in blood pressure following discontinuation of Clonidine therapy can be reversed by administration of oral Clonidine hydrochloride or by intravenous [[phentolamine]]. If therapy is to be discontinued in patients receiving a [[beta-blocker]] and Clonidine concurrently, the beta-blocker should be withdrawn several days before the gradual discontinuation of Clonidine.
| |
| | |
| Because children commonly have gastrointestinal illnesses that lead to [[vomiting]], they may be particularly susceptible to hypertensive episodes resulting from abrupt inability to take medication.
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| {{FDA}}
| |
| | |
| | |
| | |
| | |
| [[Category:Drugs]]
| |